IL6 and cardiac arrhythmia: IL-6 is a potential therapeutic target to reduce APD and Ca2+ transient changes and decrease susceptibility of hiPSC-CMs to loss of capture and potential conduction block when cocultured with MyoFBs, which in-turn may lead to reduced electrophysiological heterogeneity at the site of hiPSC-CMs grafts and reduced risk of arrhythmia post-engraftment.